TACSTD2 and neoplasm: To further demonstrate the targeting specificity of (Rap)2-E1*-(Rap)2 vs. (Rap)2-22*-(Rap)2, we performed another study to compare their potency in a CD22-expressing, but Trop-2-negative, tumor model.